Multigene panel testing beyond BRCA1/2 in breast/ovarian cancer Spanish families and clinical actionability of findings.

Sandra BonacheIrene EstebanAlejandro Moles-FernándezAnna TenésLaura Duran-LozanoGemma MontalbanVanessa BachEstela CarrascoNeus GadeaAdrià López-FernándezSara Torres-EsquiusFrancesco MancusoGinevra CaratúAna VivancosNoemí TusetJudith BalmañaSara Gutiérrez-Enríquez Orland Diez

Published in: Journal of cancer research and clinical oncology (2018)

Eight percent of the BRCA1/2 negative patients carry pathogenic variants in other actionable genes. The multigene panel usage improves the diagnostic yield in HBOC testing and it is an effective tool to identify potentially new candidate genes.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
genome wide
gene expression
copy number
transcription factor
patient reported
genome wide identification